COMET trial finds active monitoring is a viable option for some patients with low-risk DCIS
Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who underwent active monitoring had similar two-year invasive ipsilateral breast cancer recurrence rates as ...
Dec 12, 2024
0
0